NUC-8000 / NuCana - LARVOL DELTA

Trends in AML and MDS at ASH 2021 (YouTube) - "Mikkael Sekeres...comments on key topics in myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) to be discussed at the ASH 2021 annual meeting. In the MDS space, Dr Sekeres highlights reports of IDH inhibitor use as single agents in patients with IDH1/2 mutations, as well as a number of studies of combination therapy. For AML, several studies have investigated triplet combinations with a backbone of venetoclax plus azacitidine, decitabine, or low-dose cytarabine. Dr Sekeres also comments on abstracts discussing menin inhibitors and venetoclax plus FLAG-IDA. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA."

Interview • Video